Novel aminoglycosides represented by Formulae la and lb as defined in the instant specification designed to exhibit stop codon mutation readthrough activity are provided. Also provided are pharmaceutical compositions containing the same and uses thereof in the treatment of genetic diseases and disorders such as diseases and disorders associated with stop codon mutations.